MRI-guided personalisation of neoadjuvant chemotherapy duration is associated with improved 3-year survival outcomes in patients with stage II-III HER2-positive breast cancer, a new trial reports.
Currently, no consensus exists regarding the definition of oligometastatic pancreatic ductal adenocarcinoma, its necessary diagnostic measures, and potential treatment approaches. To address these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results